News | February 09, 2010

Molecular Imaging Role Critical in Patients with Cognitive Disorders

February 9, 2010 - Nuclear medicine and molecular imaging professionals discussed the critical role of molecular imaging in the diagnostic approach to patients with cognitive disorders, as well as other clinical topics during SNM's 2010 Conjoint Mid-Winter Meetings.

Four meetings were held in succession, including the 2010 Annual Meeting and Educational Symposium of the American College of Nuclear Medicine (ACNM) and SNM's Mid-Winter Educational Symposium, Nanomedicine and Molecular Imaging Summit and Clinical Trials Network Community Workshop.

The ACNM Annual Meeting and Educational Symposium took place first and featured lectures about the use of PET/CT in the brain and neck, genitourinary system, head and neck cancer and thyroid cancer. This was the first gathering of the organization since it officially merged in September with the American College of Nuclear Physicians.

SNM's Mid-Winter Educational Symposium began at the conclusion of ACNM's meeting, keeping attendees busy with a robust schedule of in-depth educational sessions and exhibits. The symposium included numerous educational sessions designed in collaboration with SNM's councils, centers of excellence, Technologist Section (SNMTS) and Clinical Trials Network.

"Integrated Imaging for Clinical Diagnosis and Treatment of Heart Failure in 2010" updated cardiologists, nuclear medicine physicians and scientists about current understanding and recent developments in the multimodality imaging assessment of heart failure. Back by popular demand, the two-day CT case review session challenged and instructed physicians with 100 cases and 16 hours of continuing education credits.

In the session, "The Sharp Edges of Nuclear Medicine: See What's New," technologists were introduced to the newest techniques in fusion imaging, with a focus on patients with epilepsy. In addition, technologists attended a new session, cosponsored by SNMTS and the American Society of Radiologic Technologists, titled "Nuclear Medicine Unfolded: What You Need to Know." The session focused on legislative and regulatory issues that nuclear medicine technologists face, including USP , the recently reintroduced CARE bill and the Medicare Improvement Providers and Patients Act of 2008 (MIPPA).

"We think this year's educational symposium provided attendees with the most comprehensive information in nuclear medicine and molecular imaging," said Peter Herscovitch, M.D., chair of SNM's Scientific Program Committee. "We were pleased to offer yet another excellent opportunity for leaders in the field to come together in one place to share their ideas."

The Nanomedicine and Molecular Imaging Summit followed on the heels of the symposium, Jan. 31–Feb. 1. This SNM summit, which featured sessions led by more than 20 experts from a variety of fields, took an exciting look at what the future holds for nanomedicine, as well as molecular imaging's role in its development and application.

The SNM Clinical Trials Network Community Workshop capped off the mid-winter meeting on Feb.1­–2, giving participants important information about molecular imaging in clinical trials. Topics discussed included clinical research imaging technologist certification curriculum, multisite imaging challenges for investigational therapeutics clinical trials and site qualification via the SNM Clinical Trials Network phantom program.

For more information: www.snm.org

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init